Journal Club

 

2020

Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study14.09.2020 (Matthias von Rotz)
Peak CM. et al.: Individual quarantine versus active monitoring of contact for the mitigation of COVID-19: a modelling study Lancet Infect Dis 20: 1025-33 2020
1. Setting The criteria for SARS-CoV-2 Reinfection – six Possible cases
2. Clinical recurrences of COVID-19 Symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
3. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

07.09.2020 (Kai-Manuel Adam)
Diverse 3. Paper: 1. Setting The criteria for SARS-CoV-2 Reinfection – six Possible cases
2. Clinical recurrences of COVID-19 Symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
3. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing J Infect; CID Epub Epub 2020

Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species31.08.2020 (Ana Durovic)
Chamat-Hedemand S. et al.: Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections Is Dependent on Streptococcal Species Circulation Volume 142, Issue 8 720-730 2020
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study 24.08.2020 (Sandra Zingg)
Iversen K. et al.: Risk of COVID-19 in health-care workers in Denmark: an observational cohort study Lancet Infect Dis 2020 S1473-3099(20)30589-2 2020
Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use10.08.2020 (Anne-Valérie Burgener)
Rhee, Kadri, Dekker et al.: Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use JAMA Infect. Disease, 2020;3(4):e202899
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts03.08.2020 (Silvio Ragozzino)
Ikematsu H. et al.: Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts N Eng J Med 383 309-320 2020
Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial27.07.2020 (Matthias von Rotz)
von Dach E. et al.: Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. A Randomized Clinical Trial JAMA 323, Number  21 2160-2169 June 2, 2020
An mRNA Vaccine against SARS-CoV-2 – Preliminary Report20.07.2020 (Sabine Kuster)
Jackson L.A. et al.: An mRNA Vaccine against SARS-CoV-2 – Preliminary Report NEJM  July 14, 2020 DOI:10.1056/NEJMoa2022483 1-12
Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report13.07.2020 (Sandra Zingg)
Peter Horby: Effect of Dexamethasone in Hospitalized Patients with OCVID-19 – Preliminary Report medRvix preprint https://doi.org/10.1101/2020.06.22.20137273 2020
Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial29.06.2020 (Sabine Kuster)
Deftereos S.G. et al: Effect of Colchicine vs. Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial JAMA Online June 2020, Vol 3, No. 6 1 -14 2020
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial22.06.2020 (Mihaela Sava)
Zhu FC et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial The Lancet 395 1845-54
2020 Mai
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
15.06.2020 (Kai-Manuel Adam)
Diverse 3 Paper:
1. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection
2. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
3. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial
medRxiv preprint Epub Epub 2020 Juni
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis08.06.2020 (Matthias von Rotz)
Mehra MR. et al.: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis The Lancet Nur online erschienen. 22. Mai 2020
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study25.05.2020 (Aurélien Emmanuel Martinez)
Verdoni L. et al.: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Lancet Online online 2020
Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure18.05.2020 (Ana Durovic)
Kucirka L.M. et al.: Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure ACP Journals doi.org/10.7326/M20-1495 2020
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies11.05.2020 (Anne-Valérie Burgener)
Williams CM et al.: Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospektive observational studies Lancet Infect Dis. Volume 20 607-617
An analysis of SARS-CoV-2 viral load by patient age04.05.2020 (Silvio Ragozzino)
Terry CJ. et al: An analysis of SARS-CoV-2 viral load by patient age
Preprint – https://virologie-ccm.charite.de/
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial20.04.2020 (Sandra Zingg)
Mahévas M. et al: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial BMJ (medRxiv) 04/2020
Virological assessment of hospitalized patients with COVID-1906.04.2020 (Mihaela Sava)
Wölfel R et al.: Virological assessment of hospitalized patients with COVID-19
Nature 2020, published online April 1st , 2020
Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents30.03.2020 (Matthias von Rotz)
Kampf G. et al.: Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents Journal of Hospital Infection 104 246-251 2020
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study10.02.2020 (Sabine Kuster)
Nashan Chen et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet Infectious Disease Published Online January 29, 2020 1-7 2020
Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial20.01.2020 (Elisabeth Wehrle)
Kaye K.: Fosfomycin for Injection (ZTI-01) Versus PiperacillinPiperacillintazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial CID 69 2045-2056 2019
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials13.01.2020 (Mihaela Sava)
Campbell R J. et al.: Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis oft wo randomised controlled trials Lancet Infect Dis 2019 Online First 2019
Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in 
critically ill
06.01.2020 (Sandra Zingg)
Gloria Wong: Β-Lactam pharmacodynamics in Gram-negative bloodstream infections in critically ill J Antimicrob Chemother 75 429-433 2020